

**V.V. McLaughlin** has received fees for speaking and/or consulting from Actelion, Bayer, Gilead, and United Therapeutics. The University of Michigan has received research grants for multicentre trials from Actelion, Bayer, Novartis, Gilead and United Therapeutics.

**H-J. Seyfarth** has received fees for speaking at conferences and/or consultations from Actelion, Bayer, GSK, Lilly and Pfizer.

**T. Bull** has received an investigator initiated grant from United Therapeutics. He has received fees for consulting for Lung LLC and Actelion pharmaceuticals.

**C.D. Vizza** has received fees for serving as a speaker, consultant and an advisory board member, from the following companies: Actelion, Bayer, Dompè, GSK, Italfarmaco, Lilly, Pfizer, United Therapeutics.

**M. Gomberg-Maitland** reports that the University of Chicago has received grants from Actelion, Gilead, GlaxoSmith Kline, Medtronic, Novartis, Pfizer and United Therapeutics for clinical trial research. She serves as a consultant on DSMBs, steering committees and clinical events committees for Actelion, Gilead, Ikaria, Medtronic, Pfizer and United Therapeutics. She has received honoraria for CME symposium and education from ABcomm, Heathmatters CME and medscape.

**I.R. Preston** has received funds for research from Actelion, Gilead, Novartis, Geno and United Therapeutics, and fees for consulting from Actelion, Bayer, Gilead, United Therapeutics, Novartis and Pfizer, and fees for speaking from Actelion, Bayer, Gilead and United Therapeutics.

**J.A. Barberà** has received fees for speaking at conferences and/or consultations from Actelion, Bayer, GSK and Pfizer.

**P.M. Hassoun** has received fees for participating at advisory boards from Gilead, Pfizer, Merck, Bayer and Novartis.

**M. Halank** has received honoraria for lectures and consulting and has received reimbursements for attending symposiums by Actelion, Bayer, GlaxoSmithKline, Lilly, Novartis, Pfizer and United Therapeutics.

**X. Jais** has received speaker and/or consultant fees from Actelion, Bayer, GSK, Lilly, Novartis and Pfizer. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.

**M.M. Hoepfer** has received fees for speaking at conferences and/or consultations from Actelion, Bayer, Gilead, GSK, Lilly, LungRx, Novartis and Pfizer.

**M. Humbert** has relationships with drug companies including Actelion, Aires, Bayer, GSK, Lilly, Novartis, Pfizer and United Therapeutics. In addition to being an investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.